Abbott Laboratories (N:ABT)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 100 Abbott Park Rd
ABBOTT PARK IL 60064-3500
Tel: N/A
Website: https://www.abbott.com
IR: See website
<
Key People
Miles D. White
Executive Chairman of the Board
Daniel Gesua Sive Salvadori
Executive Vice President - Nutritional Products
Robert B. Ford
President, Chief Executive Officer, Chief Operating Officer, Director
Robert E. Funck
Chief Financial Officer, Executive Vice President - Finance
Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Mary K. Moreland
Executive Vice President of Human Resources
John M. Capek
Executive Vice President - Ventures
Lisa D. Earnhardt
Executive Vice President - Medical Devices
John F. Ginascol
Executive Vice President - Core Diagnostics
Andrew H. Lane
Executive Vice President - Established Pharmaceuticals
   
Business Overview
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Financial Overview
For the three months ended 31 March 2020, Abbott Laboratories revenues increased 3% to $7.73B. Net income before extraordinary items decreased 8% to $544M. Revenues reflect Nutritionals segment increase of 6% to $1.9B, Established Pharmaceutical Products segment increase of 5% to $1.04B, United States segment increase of 4% to $2.86B, All other Countries segment increase of 2% to $4.87B.
Employees: 107,000 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $180,292M as of Mar 31, 2020
Annual revenue (TTM): $32,095M as of Mar 31, 2020
EBITDA (TTM): $7,775M as of Mar 31, 2020
Net annual income (TTM): $3,551M as of Mar 31, 2020
Free cash flow (TTM): $2,133M as of Mar 31, 2020
Net Debt Last Fiscal Year: $14,604M as of Mar 31, 2020
Shares outstanding: 1,768,845,326 as of Mar 31, 2020
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization